Abstract: An excipient for a pharmaceutical compound which melts at body temperature but will not spontaneously deform at higher temperatures encountered in shipment and storage comprises:______________________________________ Low MW Polyethylene glycol 75-90% (M.P. about 37.degree. C.) Medium to high MW polyethylene glycol 0-4% Long chain saturated carboxylic acid 0-4% Polyethylene oxide 0-4% (MW 100,000-5,000,000) Colloidal silica 10-20%. ______________________________________The excipient is particularly advantageous for the preparation of dosage forms for buccal administration of pharmaceutical compounds.

Abstract: An excipient for a pharmaceutical compound which melts at body temperature but will not spontaneously deform at higher temperatures encountered in shipment and storage comprises:______________________________________ Low MW Polyethylene glycol 75-90% (M.P. about 37.degree. C.) Medium to high MW polyethylene glycol 0-4% Long chain saturated carboxylic acid 0-4% Polyethylene oxide 0-4% (MW 100,000-5,000,000) Colloidal silica 10-20%. ______________________________________The excipient is particularly advantageous for the preparation of dosage forms for buccal administration of pharmaceutical compounds.

Abstract: A matrix for a buccal dosage form which melts in the oral cavity at body temperature but will not spontaneously deform at higher temperatures encountered in shipment and storage comprises:______________________________________ Low MW Polyethylene glycol 75-90% (M.P. about 37.degree. C.) Medium to high MW polyethylene glycol 0-4% Long chain saturated carboxylic acid 0-4% Polyethylene oxide 0.1-4% (MW 100,000-5,000,000) Colloidal silica 10-20%.

Abstract: A sustained release composition for releasing a biologically active compound into an aqueous liquid environment comprises a biologically active compound dispersed in a matrix which progressively erodes in contact with a liquid environment, the matrix having a melting point below the melting point of the biologically active compound, and the matrix comprising a mixture ofa.) 5% to 100% by weight of a solid water-dispersible polyether diol having a molecular weight from about 1000 to about 20,000, selected from the group consisting of polyethylene glycols and polyethylene oxide-polypropylene oxide block copolymers, andb.) 95 to 0% by weight of an erosion rate modifier which is an amphiphilic compound insoluble in the aqueous liquid.Dosage forms comprising the sustained release composition are prepared by molding, particularly by injection molding.

Abstract: An exicipient for a pharmaceutical compound which melts at body temperature but will not spontaneously deform at higher temperatures encountered in shipment and storage comprises:______________________________________ Low MW Polyethylene glycol 75-90% (M.P. about 37.degree. C.) Medium to high MW polyethylene glycol 0-4% Long chain saturated carboxylic acid 0-4% Polyethylene oxide 0-4% (MW 100,000-5,000,000) Colloidal silica 10-20%. ______________________________________The excipient is particularly advantageous for the preparation of dosage forms for buccal administration of pharmaceutical compounds.

Abstract: The invention is directed to a pharmaceutical composition comprising a microencapsulated potassium salt encapsulated in a shell wall consisting essentially of from about 85% to about 97% ethyl cellulose and from about 3% to about 15% of an amphiphile based on the weight of the shell wall; wherein the weight of said shell wall is from about 3% to about 15% of the total weight of the microencapsulated potassium salt.

Abstract: A sustained release composition for releasing a biologically active compound into an aqueous liquid environment comprises said biologically active compound dispersed in a bioerodible matrix, the matrix comprising a mixture of (a.) 5% to 95% by weight of a solid water-dispersible polyether diol having a molecular weight from about 1000 to about 20,000K selected from the group consisting of polyethylene glycols and polyethylene oxide-polypropylene oxide block copolymers, and(b.) 95 to 5% by weight of an erosion rate modifier which is an amphiphilic compound insoluble in the aqueous liquid.Dosage forms comprising the erodible matrix are prepared by molding, particularly by injection molding.

Abstract: A sustained release composition for releasing a biologically active compound into an aqueous liquid environment comprises said biologically active compound dispersed in a bioerodible matrix, the matrix comprising a mixture ofa. 5% to 99.5% by weight of a solid water-dispersible polyether diol having a molecular weight from about 1000 to about 20,000, andb. 95 to 0.5% by weight of an erosion rate modifier which is an amphiphilic compound insoluble in the aqueous liquid.Dosage forms comprising the erodible matrix are prepared by molding, particularly by injection molding.

Abstract: Buccal dosage forms for transmucosal administration of drugs comprise a pharmaceutical compound dispersed in an erodible matrix comprisingfrom about 20 to about 75 percent by weight of a low molecular weight polyethylene glycol component,from about 2 to about 65 percent by weight of a medium or high molecular weight polyethylene glycol component,from about 1% to about 40% percent by weight of an auxiliary high molecular weight polymer.Preferred auxiliary high molecular weight polymers are polyethylene oxide and polyvinylpyrrolidone which improve the molding properties of the matrix and provide water-activated adhesive properties to the compositions to provide a buccal dosage form.

Abstract: A sustained release composition for releasing a biologically active compound into an aqueous liquid environment comprises the biologically active compound dispersed in a bioerodible matrix, the matrix comprising a mixture of(a.) 5% to 99.5% by weight of a solid water-dispersible polyether diol having a molecular weight from about 1000 to about 20,000, and(b.) 95 to 0.5% by weight of an erosion rate modifier component comprising a combination of stearyl alcohol and stearic acid.Dosage forms comprising the erodible matrix are prepared by molding, particularly by injection molding.

Abstract: A sustained release composition for releasing a biologically active compound into an aqueous liquid environment comprises said biologically active compound dispersed in a bioerodible matrix, the matrix comprising a mixture of5 to 95% by weight of a polyethylene glycol having a molecular weight of from about 1000 to about 20,000, and95 to 5% by weight of an erosion rate modifier which is an amphiphilic compound insoluble in the aqueous liquid.Dosage forms comprising the erodible matrix are prepared by molding, particularly by injection molding.